Now showing items 1-2 of 2

    • Phase II Study of Monthly Pasireotide LAR (SOM230C) for Recurrent or Progressive Meningioma 

      Norden, A. D.; Ligon, Keith Lloyd; Hammond, Samantha N.; Muzikansky, A.; Reardon, David Allen; Kaley, Thomas J.; Batchelor, Tracy Todd; Plotkin, Scott; Raizer, Jeffrey J.; Wong, Eric T.; Drappatz, Jan; Lesser, Glenn J.; Haidar, Sam; Beroukhim, Rameen; Lee, Eudocia Quant; Doherty, Lisa; Lafrankie, Debra; Gaffey, S. C.; Gerard, Mary; Smith, Katrina H.; McCluskey, C.; Phuphanich, Surasak; Wen, Patrick Yung Chih (Ovid Technologies (Wolters Kluwer Health), 2014)
      Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective. Methods: Pasireotide LAR is a long-acting somatostatin analog that may ...
    • The role of whole brain radiation therapy in the management of melanoma brain metastases 

      Dyer, Michael A; Arvold, Nils D; Chen, Yu-Hui; Pinnell, Nancy E; Mitin, Timur; Lee, Eudocia Q; Hodi, F Stephen; Ibrahim, Nageatte; Weiss, Stephanie E; Kelly, Paul J; Floyd, Scott R; Mahadevan, Anand; Alexander, Brian M (BioMed Central, 2014)
      Background: Brain metastases are common in patients with melanoma, and optimal management is not well defined. As melanoma has traditionally been thought of as “radioresistant,” the role of whole brain radiation therapy ...